Simcyp launches "virtual lab rat" simulator
This article was originally published in Scrip
Executive Summary
Simcyp, a UK-based developer of platforms for pharmacokinetic modelling and simulation in virtual populations, has launched a "virtual lab rat" for the in silico prediction of drug kinetics. Symcyp Rat 2008 will model how compounds are absorbed, distributed, metabolised and excreted by the body, providing an insight into how medicines might behave in practice. The system can mimic real-life experimental scenarios, including whether test animals are fed at the time of dosing and the amount of fluid that is administered with an oral dose, Professor Amin Rostami-Hodjegan, Simcyp's director of R&D, said. The simulator contains databases of commonly used drugs which allow the properties of new medicines to be compared with those that are already available.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.